Sara M. Tolaney
Leads Dana-Farber's breast oncology division and many of the trials that moved ADCs and de-escalated therapy into breast cancer care.
Led the APT trial establishing adjuvant paclitaxel-trastuzumab for small HER2-positive tumours, and is a principal investigator across the DESTINY, TROPION and HER2CLIMB programmes and of trials of sacituzumab govitecan in TNBC.
| Title | Journal | Year |
|---|---|---|
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer | New England Journal of Medicine | 2015 |
| Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer (TROPION-Breast01) | Journal of Clinical Oncology | 2025 |
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
Women with hormone-receptor-positive, HER2-negative breast cancer that has spread to lymph nodes and has other high-risk features can now be offered two years of abemaciclib alongside their hormone therapy, with a durable reduction in relapse. It does not apply to node-negative or low-risk disease, and the diarrhoea and cost are real trade-offs to discuss.
Pages like this
not linked directly; found by shared links- PersonJoohyuk Sohn
Shares monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer, Datopotamab deruxtecan, TROP2, Trastuzumab deruxtecan.
- PersonJavier Cortés
Shares DESTINY-Breast09, monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer, ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Trastuzumab deruxtecan.
- PersonSara A. Hurvitz
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
- PersonHope S. Rugo
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, TROP2, Antibody-drug conjugate (ADC).
- IdeaTROP2 PET to choose and sequence TROP2 ADCs
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, Datopotamab deruxtecan, TROP2.
- TrialASCENT
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, TROP2, Triple-negative breast cancer (TNBC).
- PairingCaution: TOP1 ADC immediately after TOP1 ADC
Shares Sacituzumab govitecan, Datopotamab deruxtecan, Trastuzumab deruxtecan, Triple-negative breast cancer (TNBC).
- PairingTROP2 PET → TROP2 ADC selection
Shares Sacituzumab govitecan, Datopotamab deruxtecan, TROP2, Antibody-drug conjugate (ADC).